Skip to content
value.today
Talphera, Inc. logo

Talphera, Inc.

TLPH
$57 Mmarket cap on Oct 29, 2026+335.6% since Jan 2024
Compare
World rank
#20,851
Revenue
$5 M
For year ending December-2025
value.today research
Net income
$-40 M
-746.3% margin
value.today research
Employees
12
As of December 31, 2025
value.today research

Talphera, Inc. in brief

Talphera, Inc. is a listed company in the Pharmaceutical industry, based in California, USA. It was founded in 2005. Its market value was $57 M on 29 October 2026, which makes it the 20,851st largest listed company in the world and the 3,807th largest in the USA on this site. In the year to December 2025 it had sales of $5 M and a net loss of $40 M. It employs about 12 people. Its shares trade under the symbol TLPH (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Talphera, Inc.

Our portfolio is principally focused on our lead product candidate, Niyad (nafamostat mesylate), for use as a regional anticoagulant during continuous renal replacement therapy, or CRRT. In addition, we may develop LTX-608, a nafamostat formulation for direct IV infusion for one or more of the following indications: disseminated intravascular coagulation, or DIC, acute respiratory distress syndrome, or ARDS, acute pancreatitis, or as an anti-viral treatment. We have two pre-filled syringe product candidates that have been explored but are being evaluated for discontinuation.

In January 2022, we acquired Lowell Therapeutics, Inc., or Lowell, a privately held company, pursuant to the Agreement and Plan of Merger, dated as of November 14, 2021, or the Merger Agreement, in a transaction for consideration of approximately $32.5 million plus net cash acquired and certain other adjustments, and which included up to approximately $26.0 million of contingent consideration payable in cash or stock at our option, upon the achievement of regulatory and sales-based milestones. In connection with the Merger Agreement, we acquired Niyad and LTX-608 (lyophilized vials of nafamostat for infusion into the extracorporeal circuit or direct IV infusion to the patient, respectively), an in-process research and development, or IPR&D, asset. For additional information regarding the Merger Agreement, see Note 4, “Asset Acquisition” to our consolidated financial statements in this Annual Report on Form 10-K.

Talphera, Inc. timeline

6 events, 2005–2023
  1. 2005
  2. 🏁
    · approximate
    Founded
  3. 2008
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2011
  6. 🔔
    · approximate
    Initial public offering on Nasdaq
  7. 🔔
    Initial public offering as Acelrx Pharmaceuticals Inc
    Final prospectus filed with the SEC on 11 February 2011; shares registered for exchange trading on 1 February 2011.
  8. 2020
  9. 💰
    Record revenue of $5 million
    FY2020, the highest of the 6 years on record.
  10. 2023
  11. ✎
    Renamed Talphera, Inc.
    Formerly Acelrx Pharmaceuticals Inc.

Events of Talphera, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$44 M$89 M$133 M$177 M2020202120222023202420252026

World rank over time

▼ down 4,169 places since 2020
2020-01-01: #16722#16,72220202021-01-01: #17765#17,76520212022-01-07: #25461#25,46120222022-12-25: #30245#30,24520222023-07-30: #30233#30,23320232024-01-05: #30440#30,44020242026-10-08: #21080#21,08020262026-10-29: #20891#20,8912026

Rank in USA: #3,374 (Jan 2020) · #3,622 (Jan 2021) · #4,776 (Jan 2022) · #5,407 (Dec 2022) · #5,273 (Jul 2023) · #4,463 (Jan 2024) · #3,806 (Oct 2026) · #3,811 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
10.5×
Price / book
3.3×
Free cash flow yield
-22.4%
Net margin
-746.3%
Operating margin
-249.6%
Return on equity
-236.5%
Liabilities / assets
42.7%
Net debt
$-10M
Revenue growth
-95.4%
R&D / revenue
20100.0%
Revenue per employee
$450 K
Profit per employee
$-3.4 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $2M, net income $-47M$2MFY18Fiscal year ending Dec 2019: revenue $2M, net income $-53M$2MFY19Fiscal year ending Dec 2020: revenue $5M, net income $-40M$5MFY20Fiscal year ending Dec 2021: revenue $0M, net income $-35M$0MFY21Fiscal year ending Dec 2022: revenue —, net income $48M—FY22Fiscal year ending Dec 2023: revenue $1M, net income $-18M$1MFY23Fiscal year ending Dec 2024: revenue —, net income $-13M—FY24Fiscal year ending Dec 2025: revenue $0M, net income $-14M$0MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$0M—$-13M$-14M-47633.3%
Dec 2024——$-15M$-13M—
Dec 2023$1M—$-17M$-18M-2830.8%
Dec 2022——$-25M$48M—
Dec 2021$0M-93.0%$-18M$-35M-9236.8%
Dec 2020$5M+136.7%$-41M$-40M-745.0%
Dec 2019$2M+6.5%$-54M$-53M-2324.9%
Dec 2018$2M—$-36M$-47M-2193.0%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-11M————
Dec 2024$-13M$0M$-13M——
Dec 2023$-17M$0M$-18M$-1.29—
Dec 2022$-28M$0M$-29M$5.72—
Dec 2021$-30M$2M$-32M$-5.86—
Dec 2020$-39M$2M$-40M$-0.47—
Dec 2019$-51M$3M$-55M$-0.67—
Dec 2018$-29M$1M$-30M$-0.81—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-2M—Dec ’24Three months to Mar 2025: revenue $0M, net income $-3M$0MMar ’25Three months to Jun 2025: revenue —, net income $-3M—Jun ’25Three months to Sep 2025: revenue $0M, net income $-4M$0MSep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-4M—Dec ’25Three months to Mar 2026: revenue —, net income $-3M—Mar ’26Three months to Jun 2026: revenue —, net income $-4M—Jun ’26Three months to Sep 2026: revenue —, net income $-4M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Talphera, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$5 M
Operating income
$-13 M
Net income
$-40 M

For year ending December-2025

Balance sheet

Total assets
$30 M
Total liabilities
$13 M
Total equity
$17 M

As of December-2025

Top 51 institutional investors in Talphera, Inc.#

As of Sep 30, 2026
51 institutions held 22.2 M shares (about 42.7% of the shares outstanding) on Sep 30, 2026. The ten largest hold 38.1%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Talphera, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1AIGH Capital Management LLC4,286,502-315,000 (-6.85%)8.25%$5 MNov 2, 2026
2Rosalind Advisors, Inc.4,134,144-1,035,357 (-20.03%)7.96%$5 MNov 16, 2026
3Rock Springs Capital Management LP3,589,1860 (0.00%)6.91%$4 MNov 16, 2026
4Nantahala Capital Management, LLC3,492,519-3,492,519 (-50.00%)6.72%$4 MNov 13, 2026
5Bleichroeder LP1,307,7870 (0.00%)2.52%$2 MNov 13, 2026
6Vanguard Capital Management LLC1,001,645+299,768 (+42.71%)1.93%$1 MNov 13, 2026
7Cantor Fitzgerald, L. P.709,976-1,064,986 (-60.00%)1.37%$1 MNov 16, 2026
8Geode Capital Management, LLC465,423+36,361 (+8.47%)0.90%$1 MNov 6, 2026
9Caption Management, LLC443,118-71,851 (-13.95%)0.85%$1 MNov 16, 2026
10Diadema Partners LP378,037+224,474 (+146.18%)0.73%$0 MNov 16, 2026
11Almitas Capital LLC339,820-127,332 (-27.26%)0.65%$0 MNov 17, 2026
12Shay Capital LLC314,732-91,032 (-22.43%)0.61%$0 MNov 16, 2026
13Vanguard Fiduciary Trust Co222,3720 (0.00%)0.43%$0 MNov 13, 2026
14Gsa Capital Partners LLP179,573-29,782 (-14.23%)0.35%$0 MNov 16, 2026
15Renaissance Technologies LLC149,800+36,500 (+32.22%)0.29%$0 MNov 12, 2026
16Susquehanna International Group, LLP123,601+47,910 (+63.30%)0.24%$0 MNov 16, 2026
17Citadel Advisors LLC118,341New0.23%$0 MNov 16, 2026
18Mariner, LLC105,000+5,000 (+5.00%)0.20%$0 MNov 12, 2026
19Jane Street Group, LLC103,202+92,548 (+868.67%)0.20%$0 MNov 12, 2026
20Universal- Beteiligungs- und Servicegesellschaft mbH100,000+50,000 (+100.00%)0.19%$0 MNov 10, 2026
21Persistent Asset Partners Ltd95,987+57,019 (+146.32%)0.18%$0 MNov 13, 2026
22BlackRock, Inc.91,5480 (0.00%)0.18%$0 MNov 13, 2026
23Northern Trust Corp88,2960 (0.00%)0.17%$0 MNov 16, 2026
24HRT Financial LP88,216New0.17%$0 MNov 13, 2026
25Values First Advisors, Inc.78,273-1,412 (-1.77%)0.15%$0 MOct 23, 2026
Show all 51: investors 26 to 51
Institutional investors 26 to 51 in Talphera, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26XTX Topco Ltd68,630+40,436 (+143.42%)0.13%$0 MNov 16, 2026
27State Street Corp22,1820 (0.00%)0.04%$0 MNov 12, 2026
28Wealth Enhancement Advisory Services, LLC20,000+7,500 (+60.00%)0.04%$0 MOct 13, 2026
29Stephens Inc /ar/15,1330 (0.00%)0.03%$0 MNov 12, 2026
30Choreo, LLC13,000New0.03%$0 MOct 28, 2026
31UBS Group AG12,094-117,822 (-90.69%)0.02%$0 MNov 10, 2026
32Onyx Bridge Wealth Group LLC11,5000 (0.00%)0.02%$0 MOct 16, 2026
33Welch Group, LLC10,000New0.02%$0 MOct 29, 2026
34Simplex Trading, LLC8,434New0.02%$0 MNov 4, 2026
35Group One Trading LLC8,2130 (0.00%)0.02%$0 MNov 10, 2026
36Vanguard Global Advisers, LLC5,467-24,194 (-81.57%)0.01%$0 MNov 13, 2026
37Steward Partners Investment Advisory, LLC1,0000 (0.00%)0.00%$0 MNov 13, 2026
38Wells Fargo & Company/mn6000 (0.00%)0.00%$0 MNov 16, 2026
39Tower Research Capital LLC (TRC)314New0.00%$0 MNov 16, 2026
40Osaic Holdings, Inc.2850 (0.00%)0.00%$0 MNov 12, 2026
41FMR LLC205New0.00%$0 MNov 10, 2026
42BNP Paribas Financial Markets1360 (0.00%)0.00%$0 MNov 12, 2026
43SBI Securities Co., Ltd.111-4 (-3.48%)0.00%$0 MOct 22, 2026
44Arax Advisory Partners810 (0.00%)0.00%$0 MNov 12, 2026
45Morgan Stanley46+36 (+360.00%)0.00%$0 MNov 13, 2026
46Larson Financial Group LLC300 (0.00%)0.00%$0 MNov 5, 2026
47Flagship Wealth Advisors, LLC50 (0.00%)0.00%$0 MNov 3, 2026
48Barclays PLC2-959 (-99.79%)0.00%$0 MNov 6, 2026
49Caitong International Asset Management Co., Ltd2New0.00%$0 MOct 29, 2026
50Citigroup Inc1New0.00%$0 MNov 4, 2026
51Global Retirement Partners, LLC10 (0.00%)0.00%$0 MNov 10, 2026

Mutual funds holding Talphera, Inc.#

6 funds hold shares worth $1 M (about 2.0% of the company). Since their previous reports 3 added shares and 1 sold, buying $0 M net.
Mutual funds holding Talphera, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.440,104$0 M0.85%<0.01%−0.3%Jun 30, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.261,773$0 M0.50%<0.01%newJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC208,775$0 M0.40%<0.01%+4.7%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC63,382$0 M0.12%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC52,389$0 M0.10%<0.01%+14%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC16,366$0 M0.03%<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 6 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Talphera, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$276 K
5 purchases, 4 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$276 K
open market only
Insiders on file
31
since
$150 K-$119$0Dec 2023: bought $7 K (1 trades), sold $0 (0 trades)Dec 23Jun 2024: bought $16 K (5 trades), sold $0 (0 trades)JunAug 2024: bought $8 K (1 trades), sold $0 (0 trades)AugNov 2024: bought $4 K (1 trades), sold $0 (0 trades)NovDec 2024: bought $3 K (1 trades), sold $119 (1 trades)DecApr 2025: bought $126 K (1 trades), sold $0 (0 trades)AprFeb 2026: bought $150 K (4 trades), sold $0 (0 trades)FebMar 2026: bought $126 K (1 trades), sold $0 (0 trades)Mar
Bought (open market)Sold (open market)Hover a month for the totals
Talphera, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Jill Marie BroadfootDirectorGrant or award+5,100——13,647Form 4
filed Joseph TodiscoDirectorGrant or award+5,100——11,497Form 4
filed Marina BozilenkoDirectorGrant or award+5,100——14,147Form 4
filed Stephen J. HoffmanDirectorGrant or award+5,100——13,959Form 4
filed Mark A. WanDirectorGrant or award+5,100——13,959Form 4
filed Adrian AdamsDirectorGrant or award+5,100——22,709Form 4
filed Abhinav JainDirectorGrant or award+5,100——12,412Form 4
filed Shakil AslamChief Medical OfficerShares withheld for tax-4,518$0.820$4 K76,542Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Talphera, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
1.2 M
2.5% of shares · 27.72 days to cover
Shares sold short, last 24 reportsAll stocks →

Fails to deliver

  • : 462 shares at $1.09
  • : 13 shares at $1.07
  • : 6,131 shares at $1.05
  • : 150 shares at $1.16
  • : 341 shares at $1.26

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Talphera, Inc. scorecard#

Passes 2 of the 12 checks that could be worked out: strongest in financial health (1 of 3), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 29, 2026.

  • Valuation0 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median3.3×Price to book 3.3× against Pharmaceutical's median of 3.2×.
    • ✗Price to sales below its peers' median10.5×Price to sales 10.5× against Pharmaceutical's median of 3.5×.
    • ✗Free cash flow yield above 5%-22.4%Free cash flow is -22.4% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • ✓Net income higher than five years earlier-$14 M-$14 M in fiscal 2025 against -$40 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$14 MNet income -$14 M in fiscal 2025.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-114.1%-114.1% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities5.5×Current ratio 5.49 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-20.34Z-score -20.34 (distress zone) for fiscal 2025.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Talphera, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Talphera, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue0.000.70r2.85.42.32.28.017
Cost of revenue———2.63.86.06.84.01112
Research and development6.06.75.53.3r4.14.04.7131921
Selling, general and administrative7.58.51217r3136452117—
General and administrative———————211716
Operating expenses———————384749
Total costs and expenses14151825r3946563847—
Operating income−13−15−17−25r−36−41−54−36−39−32
Interest expense and finance costs—00.11.1r2.33.32.52.23.32.8
Other non-operating income (expense)−0.92.26.684r0.90.61.0−11−14−11
Income before tax——−1059r−35−40−53−47−52−43
Income tax0000.00.00.00.00.0−0.7−0.0
Income from continuing operations−14−13−1059——————
Income from discontinued operations0.10−8.1−11——————
Net income attributable to shareholders−14−13−1848−35−40−53−47−52−43
Earnings per share, basic-0.34-0.50-1.295.73-5.86r-0.47-0.67-0.81-1.10-0.95
Earnings per share, diluted——-1.295.72-5.86r-0.47-0.67-0.81-1.10-0.95
Shares, weighted average (basic)4226147.46.0———4745
Shares, weighted average (diluted)——147.46.0r8579584745
Balance sheet
Cash and cash equivalents5.98.95.7157.7r22r15885380
Short-term investments1403.70.5391651187.6—
Receivables———0.30.20.60.40.01.55.8
Inventory———1.21.11.63.30.91.02.2
Other current assets0.50.62.2r1.9r2.61.71.8r1.00.50.8
Current assets219.412r2550r47721086389
Property, plant and equipment———10161615111111
Right-of-use (leased) assets———0.1r4.33.23.9———
Other intangible assets8.88.88.88.80—————
Total assets3018204778669112176100
Accounts payable0.50.71.31.3r2.12.71.72.11.41.6
Debt due within a year——05.4r8.88.74.68.67.72.9
Current liabilities3.82.64.514191814161410
Long-term debt———05.013213.41119
Lease liabilities (non-current)———3.03.82.63.6———
Total liabilities13106.326114122133116112105
Retained earnings−472−457−444−426−474−438−398−345−298−246
Shareholders' equity178.01422−36−56−414.3−37−5.3
Total liabilities and equity3018204778669112176100
Shares outstanding491717r8.26.8r9980795145
Cash-flow statement
Depreciation and amortization—00.31.62.01.91.70.61.72.1
Share-based compensation0.71.01.72.94.64.45.15.24.34.5
Cash from operating activities−11−13−17−28−30−39−51−29−30−29
Capital expenditure—0−0.1−0.4−1.8−1.9−3.5−0.8−2.4−3.7
Acquisitions, net of cash acquired——0−1.7−0.8—————
Cash from investing activities−143.8−0.536−2634−37−11−10.01.8
Debt issued—————0250——
Debt repaid—0−5.4−8.4−8.8−4.7−3.5−7.7−3.5—
Shares issued————45211.28216—
Cash from financing activities23123.5−0.54217147512−0.0
Change in cash−3.03.1−157.6−1513−7335−27−28
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Talphera, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$1.1 M
Other top executives, average
$691 K
the CEO earned 1.6× this
$100 invested is now
$50
Talphera, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Chief executive$1.1 M$1.5 M$691 K$50
2024Chief executive$1.0 M$845 K$643 K$23
2023Chief executive$1.2 M$1.0 M$778 K$33

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Talphera, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 4 · Directors and officers 5 · Material agreement 3 · Unregistered share sale 4 · Shareholder vote 3 · Results announced 11

Talphera, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Results announced8-K
Unregistered share sale8-K
Delisting notice8-K
Results announced8-K
Directors and officersShareholder vote8-K
Unregistered share sale8-K
Directors and officers8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Delisting notice8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Delisting notice8-K
Delisting notice8-K
Results announced8-K
Material agreement8-K
Directors and officersResults announced8-K
Directors and officersShareholder vote8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

3 private funding rounds before listing

Private share sales · funding history

Private share sales of Talphera, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2025$17 MPrivate placement after listing$10 to $50 million13equity, optionsSEC
Apr 2025$5 MPrivate placement after listing$2 to $10 million11equity, optionsSEC
Jan 2024$6 MPrivate placement after listing$2 to $10 million6optionsSEC
Jul 2023$10 MPrivate placement after listing$10 to $50 million10equity, optionsSEC
Jan 2022$5 MPrivate placement after listing$2 to $10 million32equitySEC
Jun 2012$10 MPrivate placement after listing$10 to $50 million10equity, optionsSEC
Jun 2011$21 MNo. 3$10 to $50 million2debt, optionsSEC
Sep 2010$8 MNo. 2$2 to $10 million8debt, optionsSEC
Nov 2009$15 MNo. 1$10 to $50 million8equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at Talphera, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
19
2015–2015
Latest
19 people
2015-03-19
Talphera, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2015··19·········19
Talphera, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
19 people (36% of workforce)Restructuring planSEC 8-K“The cost reduction plan will reduce the Company’s workforce by 19 employees, approximately 36% of total headcount, in the first quarter of 2015.”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Talphera, Inc. compares in Pharmaceutical

  • Market cap$57 M · higher than 13% of 393
  • Revenue$5 M · higher than 6% of 324
  • Net margin-746.3% · higher than 0% of 313
  • Price / sales10.5× · lower than 10% of 219
  • Price / book3.3× · lower than 34% of 207
  • FCF yield-22.4% · higher than 15% of 69

Peer comparison · Pharmaceutical

CompanyMarket capP/ENet marginRev. growth
Talphera, Inc.🇺🇸$57 M—-746.3%—
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Amgen Inc.🇺🇸$249.2 B26.5×24.1%+9.9%
AstraZeneca PLC🇬🇧$242.6 B23.7×17.4%+8.6%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 29, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, value.today research, SEC filing.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Talphera, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Talphera, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Talphera, Inc.? Suggest a correction